Jing Gong - Concepedia

Author

Jing Gong

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Gong, Jing, J Gong, Jing Gong, Jing Jue Gong, Jingsong GONG

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Princess Margaret Cancer Centre University of Oxford Massachusetts General Hospital Hospital Universitari i Politècnic La Fe

About

Jing Gong is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	381
2	Engineering	2	2	100
3	Health Sciences	2	2	64
4	Biomolecular Engineering	2	2	100
5	Biomedical Engineering	1	1	73

Jing Gong

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide Hongxia Wang, Ziyuan Song, Yeh‐Hsing Lao, Proceedings of the National Academy of Sciences	2018	269
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial Courtney D. DiNardo, Andre C. Schuh, Eytan M. Stein, The Lancet Oncology Phase 1BHematological MalignancyAzacitidine Versus AzacitidineMedicineMixed-phenotype Acute Leukemia	2021	185
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein, Journal of Clinical Oncology	2020	170
Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy Tzu‐Chieh Ho, Hye Sung Kim, Yumei Chen, Science Advances	2021	112
Endosomal signaling of delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain Nestor N. Jiménez-Vargas, Jing Gong, Matthew Wisdom, Proceedings of the National Academy of Sciences	2020	104
A Versatile Nonviral Delivery System for Multiplex Gene‐Editing in the Liver Jing Gong, Hongxia Wang, Yeh‐Hsing Lao, Advanced Materials EngineeringImmunologyGene DeliveryBiomedical EngineeringNanomedicine	2020	73
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma Paul G. Richardson, Suzanne Trudel, Rakesh Popat, New England Journal of Medicine	2023	68
Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study Courtney D. DiNardo, Andre C. Schuh, Eytan M. Stein, Blood	2019	45
Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant<i>-IDH2</i> (<i>mIDH2</i>) newly diagnosed acute myeloid leukemia (ND-AML). Courtney D. DiNardo, Andre C. Schuh, Eytan M. Stein, Journal of Clinical Oncology Hematological MalignancyOncologyHealth SciencesMedicineAcute Myeloid Leukemia	2020	37
Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Courtney D. DiNardo, Anthony S. Stein, Amir T. Fathi, Blood	2017	34

Page 1